Pharmacogenetics and future drug development and delivery

Lancet

Volumn 355, Issue 9212, 2000, Pages 1358-1361

  Roses, Allen D ^a,b  

^a GLAXOSMITHKLINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENOXAPROFEN; DEXFENFLURAMINE; ENCAINIDE; TERFENADINE; TIENILIC ACID; TROGLITAZONE; ZOMEPIRAC;

ADVERSE DRUG REACTION; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG TARGETING; GENE TARGETING; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW;

EID: 0034655976     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02126-7     Document Type: Note

References (15)

1. Roses A.D. The Alzheimer diseases. Appel S.H. Current neurology: vol XIV. 1994;111-141 Mosby, Chicago.
2. Aitman T.J., Todd J.A. Molecular genetics of diabetes mellitus. Baillières Clin Endocrinol Metab. 9:1995;631-656.
3. Roses A.D. Apolipoprotein E alleles as risk factors in Alzheimer disease. Annu Rev Med. 47:1996;387-400.
4. Scott W.K., Grubber J.M.et al. Further evidence linking late-onset Alzheimer disease with chromosome 12. JAMA. 281:1999;513-514.
5. Murrell J.R., Koller D.et al. Familial multiple-system tauopathy with presenile dementia is localized to chromosome 17. Am J Hum Genet. 61:1997;1131-1138.
6. Spillantini M.G., Crowther R.A.et al. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA. 95:1998;6469-6473.
7. Kuivenhoven J.A., Jukema J.W., Zwinderman A.H.et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progession of coronary athersclerosis. N Engl J Med. 338:1998;86-93.
8. 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet. 350:1997;995-999.
9. Lai E., Riley J., Purvis I., Roses A. A 4-Mb high-density single nucleotide polymorphism-based map around human APOE. Genomics. 54:1998;31-38.
10. Brookes A.J. The essence of SNPs. Gene. 234:1999;177-186.
11. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients. a meta-analysis of prospective studies JAMA. 279:1998;1200-1205.
12. Wood A.J., Stein C.M.et al. Making medicines safer - the need for an independent drug safety board. N Engl J Med. 339:1998;1851-1854.
13. Faster access to modern treatment: how NICE appraisal will work: a discussion paper. 1999;NHS Executive, Leeds.
14. Mather D.B., Sullivan S.D., Augustein D., Fullerton P., Atherton D. Incoporating clinical outcomes and economic consequences into drug formulary decision. a practical approach Am J Managed Care. 5:1999;277-285.
15. Fijal B.A., Hall J.M., Witte J.S. Clinical trials in the genomic era. effects of protective genotypes on sample size and duration of trial 2000 Controlled Clinical Trials. 21:2000;7-20.